Trials / Conditions / Cholangiocarcinoma of the Extrahepatic Bile Duct

Cholangiocarcinoma of the Extrahepatic Bile Duct

19 registered clinical trials studyying Cholangiocarcinoma of the Extrahepatic Bile Duct — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study NCT06964425	University Hospital Olomouc	N/A
Completed	Recurrence After Whipple's (RAW) Study NCT04596865	University Hospital Plymouth NHS Trust	—
Completed	EUS Evaluation of CBD Diameter in Malignant Obstructive Jaundice NCT03494023	Clinical Hospital Colentina	—
Unknown	Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbl NCT03768375	Shanghai Jiao Tong University School of Medicine	Phase 2
Unknown	Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma NCT03772132	Shanghai Jiao Tong University School of Medicine	Phase 2
Unknown	Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder NCT02836847	Shanghai Jiao Tong University School of Medicine	Phase 2
Unknown	Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer NCT02238613	307 Hospital of PLA	N/A
Completed	Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma NCT01954745	Massachusetts General Hospital	Phase 2
Completed	CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery NCT01766219	Wake Forest University Health Sciences	Phase 1 / Phase 2
Withdrawn	Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duc NCT01859182	National Cancer Institute (NCI)	Phase 2
Completed	Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointest NCT01643499	University of Chicago	Phase 1
Terminated	Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers NCT01229111	National Cancer Institute (NCI)	Phase 2
Completed	B-Receptor Signaling in Cardiomyopathy NCT01135849	Daniel Bernstein	—
Terminated	Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers NCT00832637	New Mexico Cancer Research Alliance	Phase 2
Completed	Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors NCT00356889	National Cancer Institute (NCI)	Phase 2
Completed	S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma NCT00238212	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer NCT00033462	National Cancer Institute (NCI)	Phase 2
Terminated	BMS-247550 in Treating Patients With Liver or Gallbladder Cancer NCT00023946	National Cancer Institute (NCI)	Phase 2
Withdrawn	Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating NCT00253617	Jonsson Comprehensive Cancer Center	Phase 3